Amoroso Michael 4
4 · PRECISION BIOSCIENCES INC · Filed Jun 3, 2026
Research Summary
AI-generated summary of this filing
Precision BioSciences (DTIL) CEO Michael Amoroso Receives Award
What Happened Michael Amoroso, President & CEO and a director of Precision BioSciences (DTIL), was granted 573,888 restricted stock units (RSUs) on 2026-06-01. The Form 4 lists the award as a derivative acquisition at $0.00 per unit (no cash paid on grant). This is a grant of compensation/retention equity rather than a market purchase or sale.
Key Details
- Transaction date and filing: Grant dated 2026-06-01; Form 4 filed 2026-06-03 (filed within the two-business-day Section 16 deadline).
- Amount and price: 573,888 RSUs; reported price $0.00 (award/derivative, transaction code A).
- Shares owned after transaction: Not specified in the provided filing details.
- Footnotes: F1 — each RSU is a contingent right to one share of common stock. F2 — award vests in three substantially equal annual installments beginning February 18, 2027, subject to continued service.
Context RSUs are a form of equity compensation that convert into shares only upon vesting; they are not immediately tradable and do not indicate an outright purchase. Grants like this are typically compensation or retention-related and should be interpreted as part of the CEO’s pay package rather than a direct market signal.
Insider Transaction Report
- Award
Restricted Stock Units
[F1][F2]2026-06-01+573,888→ 573,888 total→ Common Stock (573,888 underlying)
Footnotes (2)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.
- [F2]Award vests in three substantially equal annual installments beginning on February 18, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.